Figure 4.

Hepatocytes Contribute to Liver Tumorigenesis

(A) Schematic representation of tamoxifen-treated SA^creERT2; R26-stop-EYFP mice. 5-week-old mice were fed with tamoxifen diet for 2 weeks and sacrificed at 7 weeks of age.

(B) Representative images of EYFP IHC performed in liver sections derived from SA^creERT2; R26-stop-EYFP mice treated as described in (A) (n = 3).

(C) Co-IF images of HNF4α and EYFP in liver sections derived from mice treated as described in (A) (n = 3).

(D) Quantification of percentage of hepatocytes positive for both HNF4α and EYFP, as described in (C) (n = 3).

(E) Schematic representation of tamoxifen-treated hURI-tetOFF^hep; SA^creERT2; R26-stop-EYFP mice. 5-week-old mice were treated for 2 weeks with tamoxifen and sacrificed at 65 weeks of age.

(F) Representative IF images of three different EYFP staining pattern observed in tumors from hURI-tetOFF^hep; SA^creERT2; R26-stop-EYFP mice treated as described in (E); n = 16 mice and 59 tumors.

Scale bars represent 100 μm, 50 μm, and 20 μm.